Deferasirox: for iron overload: only a third-line option.
In patients with iron overload, oral deferasirox has a less favourable risk-benefit balance than subcutaneous deferoxamine: deferasirox appears to be less effective and also has more hepatic and renal adverse effects. In second-line situations it is better to first use deferiprone (another oral treatment, with which deferasirox has not been compared), a drug with which we have more experience. However, as iron chelation can be a lifelong necessity for some patients, deferasirox can be reserved as a third-line option which may be useful in some cases.
D000284:Administration, Oral; D001565:Benzoates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005602:France; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy*; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles